Identifying active cardiovascular inflammatory disease can make all the difference in what happens next.
Cholesterol testing alone is not enough.
- 50% of heart attacks occur in patients with normal cholesterol — most cardiovascular (CV) events are due to plaque rupture1,2,3
- The PLAC® Test is the only blood test that measures Lp-PLA2 — a vascular-specific inflammatory marker critical in the formation of rupture-prone plaque4
- The higher the level of Lp-PLA2, the higher the risk of a CV event — even with normal LDL5
The PLAC Test can tell you if your patient is at risk for rupture-prone plaque
- The PLAC Test clearly identifies the atherosclerotic disease process
- Lp-PLA2 levels identify cardiovascular disease (CVD) risk assessment independent from other biomarkers — providing distinct insight into the relationship between inflammation, atherosclerosis and CV outcomes6
The PLAC Test is an actionable tool and a valuable guide for patient management
- Motivates therapeutic changes in lifestyle
- Enables you to set treatment goals and determine how aggressively you should treat risk factors
- May create a greater sense of urgency in patients to be compliant with treatment recommendations when they understand there is active disease present, and not just risk of disease
Add the PLAC Test to your lipid management strategy
- A simple blood test cleared by the FDA to aid in assessing risk of both coronary heart disease and ischemic stroke associated with atherosclerosis
- Recommended for anyone getting a lipid panel, such as patients with, but not limited to, two or more of the following risk factors:
- Lp-PLA2 testing is well-studied and published in peer-reviewed scientific literature and is recognized in the guidelines of the American Heart Association and the American Stroke Association7,8